Comparative Pharmacology
Head-to-head clinical analysis: CYKLX versus TRASYLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYKLX versus TRASYLOL.
CYKLX vs TRASYLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CYKLX is a selective phosphodiesterase 4 (PDE4) inhibitor, increasing intracellular cyclic adenosine monophosphate (cAMP) levels and reducing pro-inflammatory cytokine production.
Aprotinin is a serine protease inhibitor that forms reversible enzyme-inhibitor complexes with trypsin, plasmin, kallikrein, and chymotrypsin, thereby inhibiting fibrinolysis and reducing perioperative blood loss.
100 mg orally once daily with food.
1,000,000 KIU (kallikrein inhibitor units) IV loading dose over 10 minutes, followed by 250,000 KIU/hour continuous IV infusion during surgery; also 1,000,000 KIU added to cardiopulmonary bypass circuit prime volume.
None Documented
None Documented
Terminal half-life: 12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 2 hours (alpha phase) and 10-12 hours (beta phase); prolongation in renal impairment.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Primarily renal excretion; 70-80% of aprotinin is eliminated unchanged in urine within 48 hours; minor biliary/fecal elimination (<5%).
Category C
Category C
Antifibrinolytic
Antifibrinolytic